Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Prepaid Assets (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Prepaid Assets for 10 consecutive years, with $23.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Prepaid Assets rose 169.82% to $23.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $23.6 million, a 169.82% increase, with the full-year FY2024 number at $16.4 million, up 83.43% from a year prior.
  • Prepaid Assets was $23.6 million for Q3 2025 at Rhythm Pharmaceuticals, down from $24.7 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $24.7 million in Q2 2025 to a low of $7.3 million in Q3 2021.
  • A 5-year average of $12.2 million and a median of $10.8 million in 2022 define the central range for Prepaid Assets.
  • Peak YoY movement for Prepaid Assets: dropped 29.24% in 2021, then skyrocketed 185.24% in 2025.
  • Rhythm Pharmaceuticals' Prepaid Assets stood at $12.4 million in 2021, then decreased by 4.75% to $11.8 million in 2022, then decreased by 24.36% to $8.9 million in 2023, then skyrocketed by 83.43% to $16.4 million in 2024, then soared by 44.12% to $23.6 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Prepaid Assets are $23.6 million (Q3 2025), $24.7 million (Q2 2025), and $17.7 million (Q1 2025).